For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | ||
|---|---|---|---|---|
| Research and development | 20,925 | 15,517* | ||
| General and administrative | 8,937 | 2,571* | ||
| Total operating expenses | 29,862 | 18,087 | ||
| Loss from operations | -29,862 | -18,087* | ||
| Interest income | 2,481 | 391* | ||
| Other income | 149 | 198* | ||
| Interest expense | - | 0* | ||
| Total other income, net | 2,630 | 588* | ||
| Loss before income taxes | -27,232 | -17,499* | ||
| Federal tax at statutory rate | - | 3,675* | ||
| Permanent differences | - | -55* | ||
| Research and development credits | - | -621* | ||
| Change in valuation allowance | - | -4,241* | ||
| Income tax benefit | 0 | 0* | ||
| Net loss | -27,232 | -17,499* | ||
| Net unrealized losses on marketable securities | -584 | 15 | ||
| Total other comprehensive loss | -584 | 15* | ||
| Total comprehensive loss | -27,816 | -17,484 | ||
| Basic EPS | -1.32 | -23.468 | ||
| Diluted EPS | -1.32 | -23.468 | ||
| Basic Average Shares | 22,704,124 | 744,991 | ||
| Diluted Average Shares | 22,704,124 | 744,991 | ||
Veradermics, Inc (MANE)
Veradermics, Inc (MANE)